– USA, NY – Immune Pharmaceuticals Inc.,(NASDAQ: IMNP) announced that its Board of Directors has elected Rene-Pierre Azria as a Director and the Chair of the Transaction and Pricing Committee, with oversight on strategic and financial transactions. Mr. Azria will also be a member of the Audit Committee, the Compensation Committee and the Corporate Governance and Nomination Committee.
Upon his election, Mr. Azria commented: “I have a long-time interest in Life Sciences and in particular biopharma. Immune has a promising pipeline. Developing new drugs requires money and partnerships, and I hope that my experience in finance will help Immune accelerate certain of its initiatives. I am delighted to be part of this effort.”
Dr. Daniel Teper, founder and CEO of Immune added: “We welcome Rene-Pierre to the Immune Board of Directors. I believe that his experience with successful execution of US and cross-border transactions will be a significant asset to help drive Immune’s growth strategy.”
Mr. Azria is a Senior Partner at LionTree Advisors. Prior to joining LionTree, Mr. Azria managed Tegris LLC, the financial advisory boutique he launched in 2008. He started his career at Banque Indosuez in Tokyo, Japan, and has been an investment banker in New York since 1985, advising on financial and strategic transactions in the US, Europe and Asia. Mr. Azria was a Managing Director of Blackstone-Indosuez and the President of Financiere Indosuez, before joining Rothschild, Inc where he was a Worldwide Partner until 2007.
Mr. Azria is a director of Phoenix Group plc, a listed UK life insurance company, and of two privately owned book publishers.
Mr. Azria holds a MSc. from the HEC School of Management in France, a Trium degree from London Business School and NYU Stern Graduate School of Business, and a Bachelor of Science in Mathematics. Mr. Azria is a member of the Board of Governors and the Executive Committee of the American Jewish Committee, chairs AJC Paris and supports a number of other charitable organizations.
About Immune Pharmaceuticals
Immune Pharmaceuticals Inc. applies a personalized approach to treating and developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn’s disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development arm of AstraZeneca. Immune’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a Neuropathic Pain drug candidate ready for Phase III. AmiKet has received Orphan Drug Designation for Post-Herpetic Neuralgia.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
